Pfizer has reported positive outcomes from the Phase III BREAKWATER trial of BRAFTOVI plus cetuximab and mFOLFOX6 for ...

The investigational anti-PD-1 monoclonal antibody is showing positive topline results from the phase 3 CREST trial.

Data from a late-stage study shows that treatment with PFE's PD-1 inhibitor when added to BCG improves outcomes in certain ...

Adding a PD-1 antibody to BCG led to improved event-free survival in patients with non–muscle invasive bladder cancer.

Pfizer PFE announced positive results from the phase III CREST study that evaluated its investigational PD-1 inhibitor sasanlimab in patients with BCG-naïve, high-risk, non-muscle invasive ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational ...

Sasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma ...